Clinical trial NCT00671086: Efficacy of Ramelteon in Subjects With Chronic Insomnia
Official title: A Phase 3, Open-label, Fixed-dose Study to Determine the Safety of Long-term Administration of TAK-375 in Subjects With Chronic Insomnia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Sleep Initiation and Maintenance Disorders
Keywords: Chronic Insomnia
DIMS (Disorders of Initiating and Maintaining Sleep)
Disorders of Initiating and Maintaining Sleep
Insomnia Disorder Sleep Initiation Dysfunction
Transient Insomnia
Drug Therapy
Sleep Disorders, Intrinsic
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2008-05-05
Enrollment: 1213
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the long-term safety of Ramelteon, once daily (QD), in subjects with chronic insomnia.

Detailed description: Insomnia is characterized by difficulties initiating and maintaining sleep or complaints of non-restorative and non-refreshing sleep. Transient insomnia affects approximately one-third to one-half of the US population, based on the results of 2 surveys of representative samples of the adult US population conducted by the Gallup Organization in which respondents were asked if they had "ever had difficulty sleeping." Based on reports of "regular" or "frequent" sleep difficulty, results from the same studies suggest that approximately one-tenth of the US population experiences chronic insomnia. The ideal treatment for insomnia would reduce the latency to onset of sleep and increase total sleep time, without a negative impact on sleep architecture and without safety concerns or next-day effects.

Ramelteon is selective melatonin-1 receptor agonist under global development by Takeda Chemical Industries, Ltd., for the treatment of transient and chronic insomnia and for the treatment of Circadian Rhythm Sleep Disorders.

The purpose of this study is to obtain data in support the safety of long-term use of Ramelteon for insomnia, and to determine whether there are any adverse effects associated with extended use. Participation in this study is expected to be about. Participation in this study is anticipated to be approximately 13 months.

Eligibility criteria: Inclusion Criteria

* Participant has participated in an allowed Ramelteon study and has completed all final visit procedures for the previous study within 21 days of the Treatment Initiation Visit for this study.
* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
* Investigator believes that participant requires long-term treatment for insomnia.
* Primary insomnia as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised for at least 3 months and a history of daytime complaint(s) associated with disturbed sleep.
* Subjective sleep latency greater than or equal to 45 minutes and a subjective total sleep time less than or equal to 6.5 hours per night for at least 3 nights during the week of the Baseline Lead-in Period.
* Habitual bedtime is between 8:30PM and 12:00AM.
* Body mass index between 18 and 34, inclusive.

Exclusion Criteria

* Known hypersensitivity to Ramelteon or related compounds, including melatonin.
* Participated in any other investigational study, and/or taken any investigational drug within 30 days or five half-lives prior to Day 1 of study medication, whichever is longer. The only exception to this is prior participation in an allowed Ramelteon study.
* Sleep schedule changes required by employment (eg, shift worker) within three months prior to Day 1 of study medication, or has flown across greater than three time zones within seven days prior to screening.
* Participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to Day 1 of study medication.
* Ever had a history of seizures, sleep apnea, chronic obstructive pulmonary disease, restless leg syndrome, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder.
* History of psychiatric disorder (including anxiety or depression) within the past 12 months.
* History of drug addiction or drug abuse with the past 12 months.
* History of alcohol abuse within the past 12 months, as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised and/or regularly consumes 4 or more alcoholic drinks per day.
* Current significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, or metabolic disease, unless currently controlled and stable with protocol-allowed medication 30 days prior to Day 1 of study medication.
* Uses tobacco products during nightly awakenings.
* Any clinically important abnormal finding as determined by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.
* Positive hepatitis panel.
* Any additional condition(s) that in the Investigator's opinion would:

  * affect sleep/wake function
  * prohibit the subject from completing the study, or
  * not be in the best interest of the subject to participate in the study.
* Morning serum cortisol at the Baseline visit of less than 7.0 micro-g per dl.
* Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication, including:

  * Anxiolytics
  * Hypnotics
  * Antidepressants
  * Anticonvulsants
  * Sedating H1 antihistamines
  * Systemic steroids
  * Respiratory stimulants (eg, theophylline)
  * Decongestants
  * Over-the-counter and prescription stimulants
  * Over-the-counter and prescription diet aids
  * Central nervous system active drugs
  * Narcotic analgesics
  * Beta blockers
  * St. John's Wort
  * Kava-kava
  * Gingko biloba
  * Melatonin

Primary outcomes:
measure: Adverse Events.
timeFrame: Week 1, Months 1, 2, 3, 4, 6, 8, 10, and 12 or Final Visit.
measure: Change from Baseline in Vital Signs.
timeFrame: Week 1, Months 1, 2, 3, 4, 6, 8, 10, and 12 or Final Visit
measure: Change from Baseline in Hematology Laboratory Tests.
timeFrame: Week 1, Months 1, 2, 4, 6, 8, 10, and 12 or Final Visit.
measure: Change from Baseline in Chemistry Laboratory Tests.
timeFrame: Week 1, Months 1, 2, 4, 6, 8, 10, and 12 or Final Visit.
measure: Change from Baseline in Urinalysis Laboratory Tests.
timeFrame: Week 1, Months 1, 2, 4, 6, 8, 10, and 12 or Final Visit.
measure: Electrocardiograms.
timeFrame: Month 6 and 12 or Final Visit.
measure: Menstrual Diary Results.
timeFrame: Week 1, Months 1, 2, 4, 6, 8, 10, and 12 or Final Visit.
measure: Physical Examinations.
timeFrame: Months 2, 4, 8, 10, and 12 or Final Visit.
Secondary outcomes:
measure: Change from Baseline in Subjective Total Sleep Time.
timeFrame: Week 1, Months 1, 2, 3, 4, 6, 8, 10, 12, and 12 or Final Visit.
measure: Change from Baseline in Subjective Sleep Latency.
timeFrame: Week 1, Months 1, 2, 3, 4, 6, 8, 10, 12, and 12 or Final Visit.
measure: Clinical Global Impression Scale.
timeFrame: Months 6 and 12 or Final Visit.
Other outcomes:
Locations:
city: Birmingham
country: United States
state: Alabama
city: Mobile
country: United States
state: Alabama
city: Phoenix
country: United States
state: Arizona
city: Tempe
country: United States
state: Arizona
city: Hot Springs
country: United States
state: Arkansas
city: Little Rock
country: United States
state: Arkansas
city: Anaheim
country: United States
state: California
city: Burbank
country: United States
state: California
city: Cerritos
country: United States
state: California
city: Irvine
country: United States
state: California
city: La Jolla
country: United States
state: California
city: La Mesa
country: United States
state: California
city: Lafayette
country: United States
state: California
city: Murrieta
country: United States
state: California
city: Newport Beach
country: United States
state: California
city: Northridge
country: United States
state: California
city: Redlands
country: United States
state: California
city: Riverside
country: United States
state: California
city: San Diego
country: United States
state: California
city: San Francisco
country: United States
state: California
city: Santa Monica
country: United States
state: California
city: Boulder
country: United States
state: Colorado
city: Colorado Springs
country: United States
state: Colorado
city: Denver
country: United States
state: Colorado
city: Pueblo
country: United States
state: Colorado
city: Wheat Ridge
country: United States
state: Colorado
city: Wilmington
country: United States
state: Delaware
city: Brandon
country: United States
state: Florida
city: Clearwater
country: United States
state: Florida
city: Deland
country: United States
state: Florida
city: Edgewater
country: United States
state: Florida
city: Fort Lauderdale
country: United States
state: Florida
city: Largo
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Naples
country: United States
state: Florida
city: New Smyrna Beach
country: United States
state: Florida
city: Ocala
country: United States
state: Florida
city: Safety Harbor
country: United States
state: Florida
city: St. Petersburg
country: United States
state: Florida
city: Stuart
country: United States
state: Florida
city: Tampa
country: United States
state: Florida
city: Winter Park
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Austell
country: United States
state: Georgia
city: Blairsville
country: United States
state: Georgia
city: Macon
country: United States
state: Georgia
city: Boise
country: United States
state: Idaho
city: Chicago
country: United States
state: Illinois
city: Elk Grove Village
country: United States
state: Illinois
city: Libertyville
country: United States
state: Illinois
city: Skokie
country: United States
state: Illinois
city: Evansville
country: United States
state: Indiana
city: Fort Wayne
country: United States
state: Indiana
city: Shawnee Mission
country: United States
state: Kansas
city: Florence
country: United States
state: Kentucky
city: Louisville
country: United States
state: Kentucky
city: Paducah
country: United States
state: Kentucky
city: New Orleans
country: United States
state: Louisiana
city: Shreveport
country: United States
state: Louisiana
city: Baltimore
country: United States
state: Maryland
city: Bryan Pogue
country: United States
state: Maryland
city: Chevy Chase
country: United States
state: Maryland
city: Frederick
country: United States
state: Maryland
city: Prince Frederick
country: United States
state: Maryland
city: Rockville
country: United States
state: Maryland
city: Newton
country: United States
state: Massachusetts
city: Ann Arbor
country: United States
state: Michigan
city: Troy
country: United States
state: Michigan
city: Minneapolis
country: United States
state: Minnesota
city: Hattiesburg
country: United States
state: Mississippi
city: St. Louis
country: United States
state: Missouri
city: St. Peters
country: United States
state: Missouri
city: Wentzville
country: United States
state: Missouri
city: Billings
country: United States
state: Montana
city: Lincoln
country: United States
state: Nebraska
city: Las Vegas
country: United States
state: Nevada
city: Clementon
country: United States
state: New Jersey
city: Lawrenceville
country: United States
state: New Jersey
city: Newark
country: United States
state: New Jersey
city: Toma River
country: United States
state: New Jersey
city: Brooklyn
country: United States
state: New York
city: Kingston
country: United States
state: New York
city: Lake Success
country: United States
state: New York
city: Rochester
country: United States
state: New York
city: White Plains
country: United States
state: New York
city: Williamsville
country: United States
state: New York
city: Cary
country: United States
state: North Carolina
city: Raleigh
country: United States
state: North Carolina
city: Salisbury
country: United States
state: North Carolina
city: Wilmington
country: United States
state: North Carolina
city: Winston-Salem
country: United States
state: North Carolina
city: Beachwood
country: United States
state: Ohio
city: Cincinnati
country: United States
state: Ohio
city: Columbus
country: United States
state: Ohio
city: Dublin
country: United States
state: Ohio
city: Toledo
country: United States
state: Ohio
city: Oklahoma City
country: United States
state: Oklahoma
city: Eugene
country: United States
state: Oregon
city: Portland
country: United States
state: Oregon
city: Bala Cynwyd
country: United States
state: Pennsylvania
city: Duncansville
country: United States
state: Pennsylvania
city: Jenkintown
country: United States
state: Pennsylvania
city: Lafayette Hill
country: United States
state: Pennsylvania
city: Philadelphia
country: United States
state: Pennsylvania
city: Warwick
country: United States
state: Rhode Island
city: Anderson
country: United States
state: South Carolina
city: Columbia
country: United States
state: South Carolina
city: Greer
country: United States
state: South Carolina
city: Bristol
country: United States
state: Tennessee
city: Cordova
country: United States
state: Tennessee
city: Austin
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Plano
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Salt Lake City
country: United States
state: Utah
city: Charlottesville
country: United States
state: Virginia
city: Fairfax
country: United States
state: Virginia
city: Oakland
country: United States
state: Washington
city: Seattle
country: United States
state: Washington
city: Tacoma
country: United States
state: Washington
city: Milwaukee
country: United States
state: Wisconsin
city: Wauwatosa
country: United States
state: Wisconsin
Study officials:
affiliation: Takeda
name: VP Clinical Science
role: STUDY_DIRECTOR
References:
citation: Richardson GS, Zammit G, Wang-Weigand S, Zhang J. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J Clin Psychiatry. 2009 Apr;70(4):467-76. doi: 10.4088/jcp.07m03834. Epub 2009 Mar 10.